Zhitong Finance App learned that as demand for most of the drug combinations under the leadership of new heart disease and cancer drugs in the second quarter exceeded Wall Street expectations, the company raised sales and profit forecasts for the full year 2026. According to financial reports, the company's Q2 revenue reached US$12.97 billion, up 5.7% year over year, exceeding expectations of US$1.23 billion; adjusted earnings per share were US$2.04, exceeding expectations of $0.44.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.